Merck cough drug fails to win adcomm’s backing as FDA raises efficacy questions
The FDA’s Pulmonary-Allergy Drugs Advisory Committee voted 12 to 1 in support of rejecting Merck’s application for its chronic cough drug gefapixant, following agency …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
